glp-1 dosage chart dose conversion and safe switching guide GLP-1 Agonists Explained: Definition, How

For pharma, the race is now on to ramp up and optimise production while developing the next generation of these drugs

It can offer access to treatment for many more of the estimated 200 million Americans who are overweight or obese

The Phase 3 TRIUMPH program kicked off in 2022, with key results expected through 2026 and 2027

I would be very interested on your take on two things1) the very high discontinuation rate of these drugs (and the corresponding need for a focus on behavior change as an adjuvant/parallel to course of treatment) and, 2) the impact of significant lean muscle and bone loss during treatment w/GLP-1s

A relative cost of control analysis of once-weekly Semaglutide versus Exenatide extended-release, Dulaglutide and Liraglutide in the UK

SGLT2 Inhibitors and Cardioprotection: A Matter of Debate and Multiple Hypotheses